» Articles » PMID: 15745749

Folate Receptor Expression in Carcinomas and Normal Tissues Determined by a Quantitative Radioligand Binding Assay

Overview
Journal Anal Biochem
Publisher Elsevier
Specialty Biochemistry
Date 2005 Mar 5
PMID 15745749
Citations 419
Authors
Affiliations
Soon will be listed here.
Abstract

The folate receptor (FR) is a valuable therapeutic target that is highly expressed on a variety of cancers. The current development of folate-targeted cancer therapies has created the need for quantitating functional FRs in clinical specimens. In this article, we report on the creation of a highly sensitive radioactive binding method for quantitatively measuring FR expression in frozen tissue homogenates. Expression was positive in approximately 89% of human ovarian carcinomas but was negligible in both mucinous ovarian carcinomas and normal ovary. Expression was also significant in carcinomas of the kidney, endometrium, lung, breast, bladder, and pancreas. Normal tissues from humans and six different laboratory species were also analyzed; surprisingly, some interspecies variability in FR expression (especially in kidney, spleen, and lung tissue) was found. Interestingly, normal human lung tissue displayed high expression levels, whereas expression in normal lung of the other species was negligible. However, considering that folate-drug conjugates fail to accumulate in the lungs of patients, the consequence of this finding was not considered to be of clinical concern. Overall, this new methodology is reliable for determining functional FR expression levels in tissues, and it could possibly be a useful clinical test to determine patient candidacy for FR-targeted therapeutics.

Citing Articles

Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age.

Liu Y, Chen X, Evan T, Esapa B, Chenoweth A, Cheung A MAbs. 2025; 17(1):2470309.

PMID: 40045156 PMC: 11901361. DOI: 10.1080/19420862.2025.2470309.


Biological Evaluation of Molecular Spherical Nucleic Acids: Targeting Tumors via a Hybridization-Based Folate Decoration.

Auchynnikava T, Aarela A, Moisio O, Liljenback H, Andriana P, Iqbal I ACS Omega. 2025; 10(6):6003-6014.

PMID: 39989783 PMC: 11840764. DOI: 10.1021/acsomega.4c10047.


Folate metabolism in myelofibrosis: a missing key?.

Cerreto G, Pozzi G, Cortellazzi S, Pasini L, Di Martino O, Mirandola P Ann Hematol. 2025; 104(1):35-46.

PMID: 39847116 PMC: 11868374. DOI: 10.1007/s00277-024-06176-y.


Current research trends and hotspots of boron neutron capture therapy: a bibliometric and visualization analysis.

Cong Y, Abulimiti M, Matsumoto Y, Jin J Front Oncol. 2024; 14:1507157.

PMID: 39726703 PMC: 11669655. DOI: 10.3389/fonc.2024.1507157.


Identification and Characterization of Fully Human FOLR1-Targeting CAR T Cells for the Treatment of Ovarian Cancer.

Bethke M, Abramowski P, Droste M, Felsberger A, Kochsiek L, Kotter B Cells. 2024; 13(22).

PMID: 39594628 PMC: 11592683. DOI: 10.3390/cells13221880.